Xcout Intel
Atsena Therapeutics, Inc.
Atsena Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Durham, North Carolina, established in 2019. The firm focuses on developing novel gene therapies to treat debilitating inherited blinding diseases using proprietary vector delivery technologies. Its scientific pipeline aims to address areas of high unmet medical need in ophthalmology.
Subscribe to see Atsena Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Atsena Therapeutics, Inc. at a glance
Atsena Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $90M in March 2025. Xcout tracks 12 named people at Atsena Therapeutics, Inc., including Patrick Ritschel (Chief Executive Officer Atsena Therapeutics).
Atsena Therapeutics, Inc. leadership
- Patrick RitschelChief Executive Officer Atsena Therapeutics
- Joseph S. ZakrzewskiChair of the Board
- Patrick RitschelExecutive Officer
- Chris CarpenterDirector Sofinnova
- Christina IsacsonDirector
- Dr. Norbert RiedelDirector
6 more named people on record for Atsena Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Atsena Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $90M | — | |
| SEC Form D filing | $24.5M | — | |
| SEC Form D filing | $27.5M | — | |
| SEC Form D filing | $4.1M | — | |
| — | $4.1M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Atsena Therapeutics, Inc. competitors
A few of Atsena Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
ReCode Therapeutics is a clinical-stage genetic medicines company headquartered in Menlo Park, California, and Durham, North Carolina. The company leverages proprietary delivery systems to power a new class of disease-modifying genetic therapies.
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
Kriya Therapeutics, Inc. is a fully integrated biopharmaceutical company with operational footprints in Redwood City, California, and Research Triangle Park, North Carolina. The company develops novel gene therapies to address diverse diseases.
Ray Therapeutics, Inc. is a privately held optogenetic gene therapy company headquartered in Berkeley, California. The company focuses on reimagining vision through innovative genetic treatments and novel therapeutic solutions.
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Get Atsena Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Atsena Therapeutics, Inc. in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access